Gene Therapy for Thalassemia and Hemoglobin Disorders
Author Information
Author(s): Breda Laura, Gambari Roberto, Rivella Stefano
Primary Institution: Weill College Medical Center, Department of Pediatrics, Division of Hematology-Oncology, NY, USA
Hypothesis
Can gene therapy effectively treat thalassemia and other hemoglobinopathies?
Conclusion
Gene therapy using lentiviral vectors shows promise in correcting hemoglobin disorders like thalassemia and sickle cell disease.
Supporting Evidence
- Gene therapy has the potential to correct genetic defects in hemoglobin disorders.
- Lentiviral vectors can deliver large genomic elements necessary for effective gene therapy.
- Clinical trials are underway to test the efficacy of these gene therapy approaches.
Takeaway
Scientists are trying to fix blood disorders by changing genes in patients' cells, which could help them make healthy blood.
Methodology
The review discusses various gene therapy strategies, including the use of lentiviral vectors and gene editing techniques.
Potential Biases
There is a risk of insertional oncogenesis due to the integration of foreign genetic material.
Limitations
Current gene therapy approaches face challenges such as gene silencing and the need for improved delivery methods.
Participant Demographics
The disorders are common among Asian, African, African-American, and Mediterranean populations.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website